Form 4: Aprea Therapeutics Director Marc Duey Buys 30,000 Shares
SEC Form 4 Filing
Director Marc Duey acquired 30,000 shares of Aprea Therapeutics at $4.39 per share on October 16, 2024.
Summary
- On October 16, 2024, Marc Duey, a director of Aprea Therapeutics, Inc., purchased 30,000 shares of the company's common stock.
- The purchase price was $4.39 per share.
- Following the transaction, Duey directly owns 240,113 shares of Aprea Therapeutics.
- Duey also indirectly owns 602 shares through a spouse.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director buying shares suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's health.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive signal, but should be considered alongside other factors.
Stakeholder Impact
- The purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/16/2024 | Date of transaction: Marc Duey purchased 30,000 shares of Aprea Therapeutics. |
| 10/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.